---
title: Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic
  Cell Transplantation
date: '2024-04-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38669617/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240427180609&v=2.18.0.post9+e462414
source: Blood
description: Patients with acute myeloid leukemia (AML) who experience relapse following
  allogeneic hematopoietic cell transplantation (alloHCT) face unfavorable outcomes
  regardless of the chosen relapse treatment. Early detection of relapse at the molecular
  level by measurable residual disease (MRD) assessment enables timely intervention,
  which may prevent hematological recurrence of the disease. It remains unclear whether
  molecular MRD assessment can detect MRD before impending relapse and, if so, how
  ...
disable_comments: true
---
Patients with acute myeloid leukemia (AML) who experience relapse following allogeneic hematopoietic cell transplantation (alloHCT) face unfavorable outcomes regardless of the chosen relapse treatment. Early detection of relapse at the molecular level by measurable residual disease (MRD) assessment enables timely intervention, which may prevent hematological recurrence of the disease. It remains unclear whether molecular MRD assessment can detect MRD before impending relapse and, if so, how ...